Revises provisions relating to prescription drugs. (BDR 54-1100)
Summary
AB 411 revises Nevada’s prescription drug labeling requirements for a narrow set of medications: mifepristone, misoprostol, and their generic alternatives. Under current law, prescription labels must identify the prescribing practitioner by name. This bill allows, upon request of the prescribing practitioner, the label for those specific prescriptions to list the name of the prescribing health care practice instead of the individual practitioner.
The measure does not change who may prescribe these drugs or how they are dispensed; it only changes what identifying information may appear on the label in these circumstances. The bill is framed as a labeling/privacy measure and applies only to prescriptions for the named medications, which are commonly associated with reproductive health care.
Impact
AB 411 amends NRS 639.2801, the statute governing required prescription label contents, by creating a limited exception to the rule requiring the prescribing practitioner’s name on the label. For mifepristone, misoprostol, and their generic alternatives, the label may instead show the prescribing health care practice if the practitioner requests it. This affects pharmacies, prescribing clinicians, and patients receiving these medications, while leaving the rest of the prescription-labeling framework unchanged.
Sentiment
The bill appears to have received majority support in both chambers, passing the Assembly 26-15 and the Senate 13-8. That voting pattern suggests the measure was generally favored but not unanimously, with a meaningful minority opposed. No committee transcript is available, so the public record here shows support through passage but does not provide detailed debate or testimony.
Contention
The likely point of contention is the bill’s focus on mifepristone and misoprostol, medications closely tied to abortion and reproductive health care. Supporters likely view the change as a privacy and safety measure that allows practices to be identified instead of individual clinicians, while opponents may see it as reducing transparency or as a policy choice connected to abortion access. Because the bill is narrowly tailored, the dispute centers less on pharmacy operations and more on the policy implications of shielding individual prescriber identities for these drugs.
Requires health care practitioners prescribing opioid medications to limit amount of prescribed medication to seven-day supply, except in certain circumstances.